Quetiapine in Postpartum Depression

AstraZeneca

Status and phase: Terminated; Phase 2

Conditions: Postpartum Depressive Disorder

Treatments: Drug: Quetiapine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00681668

D1449L00023

Details and patient eligibility

About

The purpose of the study is to evaluate the efficacy and tolerability of quetiapine in female patients with postpartum depressive disorder with psychotic symptoms

Enrollment: 5 patients

Sex: Female

Ages: 18 to 39 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Provision of signed informed consent.
• Female patients with severe postpartum depressive disorders with psychotic symptoms and a minimum HAM-D cut off score of 20 points

Exclusion criteria

• Woman with pre-existing psychotic disorder
• Patients with alcohol or substance abuse or dependence
• Patients who pose an imminent risk of suicide or danger to self or others

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

5 participants in 1 patient group

Quetiapine Fumarate 150 - 800mg

Experimental group

Description:

Quetiapine 150-800mg

Treatment:

Drug: Quetiapine